Autism drug trial pulled before it even started
NCT ID NCT02947880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test the drug bumetanide in children aged 5 to 17 with autism of known cause. The goal was to see if it could improve autism symptoms. However, the trial was withdrawn before enrolling any participants, so no new information was gathered.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bumetanide
- What this could lead to
- If it worked, bumetanide might help reduce autism symptoms in some children.
- What could go wrong
- The trial was withdrawn before any participants enrolled, so no results are available. Earlier positive findings were small and need more confirmation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISTIC DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Limoges
Limoges, 87042, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a year of aripiprazole be safe for kids with autism?
- Autism behavior drug shows promise in kids
- Can a common drug tame severe autism behaviors in kids?
- Can a nasal spray help autism symptoms? new study investigates
- Kids' antipsychotic weight gain tracked for years in major safety study
- Sound therapy may tame sensory overload in fragile x kids